AN LC-MS/MS BASED BIOANALYTICAL APPROACH TO RESOLVE PHARMACOKINETIC INVESTIGATION OF ACOTIAMIDE HYDROCHLORIDE AND ITS APPLICATION TO BIOEQUIVALENCE STUDY by HALDER, DHIMAN et al.
 
Original Article 
AN LC-MS/MS BASED BIOANALYTICAL APPROACH TO RESOLVE PHARMACOKINETIC 
INVESTIGATION OF ACOTIAMIDE HYDROCHLORIDE AND ITS APPLICATION TO 
BIOEQUIVALENCE STUDY 
 
DHIMAN HALDER1, SOURAV DAS2, BALARAM GHOSH3, EASHA BISWAS1, SUKANTA ROY2, ANIRBANDEEP BOSE2, 
NAVJOT SINGH4, TAPAN KUMAR PAL1,2* 
1Bioequivalence Study Centre, Jadavpur University, Kolkata, 2TAAB Biostudy Services, Kolkata, India, 3Midnapore Medical College, 
Midnapore, 4Nri Institute of Pharmacy, Bhopal 
Email: proftkpal@gmail.com 
Received: 22 May 2020, Revised and Accepted: 28 Aug 2020 
ABSTRACT 
Objective: Acotiamide, a prokinetic drug used to treat Functional Dyspepsia, which acts by modulating gastric motility. However, in this present 
study, a simple and accurate bioanalytical method was developed for the estimation of Acotiamide in human plasma using liquid chromatography-
tandem mass spectrometry (LC-MS/MS) and validated according to US-FDA guideline.  
Methods: The method was developed in blank human blood plasma; propranolol was used as internal standard (IS). Protein Precipitation 
technique was followed for the extraction of the drug from the plasma sample. In liquid chromatography, the C18 analytical column (50 x 3 mm, 
particle size-5 μm) was used; as a mobile phase, 0.1% formic acid in Mili Q water, and ACN with methanol (1:1) used, at 0.50 ml/min flow rate. 
Detection was done by positive electrospray ionization (ESI) with a run time of 7 min in multiple reaction monitoring (MRM) mode. Eight 
calibration concentrations were taken, ranging from 1.5625-200 ng/ml for Acotiamide. Different stability studies were performed and obtained 
results found within the acceptable range. Moreover, a comparative pharmacokinetic analysis was done in 24 healthy human volunteers in a single 
dose, randomized, crossover study.  
Results: The precursor to production reaction was; m/z 451.200 → 271.200 for Acotiamide and m/z 260.300 → 116.100 m/z for IS. The obtained 
calibration curve was linear, with a mean r2value 0.9953. Among the pharmacokinetic parameters, Cmax and Tmax were 25.71±2.31,23.61±2.32 ng/ml; 
2.54±0.12, 2.43±0.21 h for reference and test samples, respectively.  
Conclusion: No major adverse events were noted in the clinical phase, the developed method was accurate and linear; obtained pharmacokinetic 
parameters hence represented.  
Keywords: Acotiamide, LC-MS/MS, Pharmacokinetics, Bioequivalence, Mass spectrometry, US-FDA guideline 
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INTRODUCTION 
Functional Dyspepsia (FD) is a disorder associated with gastric 
discomfort of the gastroduodenal region. It can affect any age or any 
socioeconomic class of society. The actual cause of FD is still not 
clear, it is believed that an irregular lifestyle and unhealthy food 
habit may be an important factor for such discomforts [1]. This also 
reduces the quality of life in individuals. The symptoms of FD 
include bothersome postprandial fullness, early satiety, 
epigastralgia, and epigastric burning, etc. FD is further divided into 
two branches i) postprandial distress syndrome (PDS, characterized 
by postprandial fullness and early satiation) and ii) epigastric pain 
syndrome (EPS, characterized by epigastric pain and burning) [2]. 
Treatment of EPS includes involved with antacids or acid 
neutralizers, but the treatment of PDS includes prokinetic agents. 
Previously, other prokinetic agents such as Domperidone, a 
dopamine receptor antagonist was used for the management of 
gastroparesis or nausea. But it exhibited a serious elevation of 
plasma prolactin level. Afterward, Cisapride a non-selective 5HT4 
blocker, was withdrawn for its cardiovascular safety issue. 
Acotiamide is a classic example of a prokinetic agent, which shows 
its prokinetic activity by inhibiting acetylcholine-esterase release in 
peripheral nerve endings and suppressing degradation of 
acetylcholine, resulting in gastric motility [3, 4]. Moreover, during 
the postprandial state, Acotiamide also inhibits duodenal and 
colonic motility in conscious dogs [5]. 
Acotiamide hydrochloride trihydrate is used in treatment for 
functional dyspepsia diagnosed by Rome III criteria recently 
approved in Japan [6]. Acotiamide is an amide containing a basic 
drug with a molecular weight of 450.56. Acotiamide exerts its 
therapeutic activity by inhibiting the muscarinic receptor, which 
results in enhanced acetylcholine release and via inhibition of 
acetylcholinesterase (AChE) activity in the stomach. However, the 
gastroprokinetic activity of Acotiamide not responsible for the 
prolongation of the QT interval, thus, it is safe in terms of cardiac 
safety issues [7, 8]. 
LC-MS/MS can be used for the bioanalysis of drugs in the body [9]. 
So in this present study, a simple and sensitive method using LC-
MS/MS for the quantification of Acotiamide from human blood 
plasma was developed to evaluate the pharmacokinetic parameters. 
Protein precipitation, a simple and cost-effective and less time-
consuming technique, was followed for the extraction purpose of 
analyte and IS from human blood plasma.  
MATERIALS AND METHODS 
Study design and volunteer enrolment 
A randomized, open-label, two treatment, two-period, two 
sequences, single-dose, crossover, comparative, pharmacokinetic 
study of two different formulations of Acotiamide i.e.; film-coated 
tablets containing Acotiamide Hydrochloride Hydride 100 mg in 24 
healthy human volunteers to evaluate the comparative 
pharmacokinetic parameters and comparative oral bioavailability. 
The study was conducted following the guidelines of the Central 
Drug Standard Control Organization (CDSCO), New Delhi, India set 
for BA/BE Studies [10]. Before the initiation of the study, healthy 
volunteers were enrolled and confirmed that volunteers are healthy 
and were not taking medications that influence esophageal motility. 
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Furthermore, an informed consent form was obtained from each 
volunteer, as per the Declaration of Helsinki. In each study period, 
after overnight fasting, drug administration was done with 240 ml of 
water. From each volunteer 182 ml blood samples were taken in 5 
ml EDTA containing vials at different times i.e., 0.5, 1.0, 1.5, 2.0, 2.25, 
2.5, 2.75, 3.0, 4.0, 6.0, 8.0, 12.0, 24.0, 48.0 and 72.0 h. The blood 
samples were centrifuged in the cold centrifuge at 3500±10 rpm and 
4±1 °C for 10 min for separation of plasma. The separated plasma 
was properly labeled with volunteer code and sampling time in 
polypropylene tubes and stored at–20±5 °C for analysis purposes. 
The following pharmacokinetic parameters Cmax, Tmax, Kel, t1/2, AUC0-t, 
and AUC0-inf were evaluated with the plasma samples, and the 
relative bioavailability of test and reference was estimated [11]. The 
calculated 90% Confidence Interval should fall within 80 to 125% 
for the Test/Reference ratios for AUC0-t, AUC0-inf, and Cmax to conclude 
bioequivalence. 
Method development and validation 
Chemicals and reagents 
Active Pharmaceutical Ingredient (API) of Acotiamide was procured 
from Akums Drugs and Pharmaceuticals Limited, Delhi, India, 
whereas Propranolol (Internal Standard) was obtained from 
SubhamBiopharma, Mumbai, India. Test and reference samples were 
also obtained from Akums Drugs and Pharmaceuticals Limited, 
Delhi-110034, India and Lupin Limited, Sikkim-737132, India, 
respectively. Formic Acid of AR Grade, water was prepared from the 
milli-Q water purification system until a conductivity of 18.2 mΩ 
was reached that supplied by millipore (elix, milli-Q A10 Academic, 
Bedford, mA, USA), methanol of HPLC grade. Acetonitrile, Dimethyl 
Sulfoxide of HPLC Grade. 
Stock solution and working standards 
The stock solution of analyte and IS (Propanolol) of 1 mg/ml were 
prepared in DMSO and kept in-20˚ C freezer. The stocks were then 
further diluted with a given mobile phase organic solvent to obtain 
the working solution of 1 µg/ml for method developments and 
further proceedings. After tuning the method with 1 µg/ml stock of 
both analyte and IS following replicates of working standards were 
spiked in plasma for obtaining the calibration curve.  
LC condition 
The LC used Shimadzu Controller CBM 20Alite with binary pumps of 
Shimadzu LC20AD, which equipped with a Shimadzu SIL20A auto-
sampler used in the following study. Separation of Acotiamide and 
Propanolol (IS) was carried out during different stages of analysis on 
a C18 column [PhenomenexKinetex, 50 mm × 3 mm (length ×inner 
diameter) particle size of 5 μm], to fulfill the study objectives. The 
mobile phase was used under gradient conditions and the 
composition was 0.1% formic acid in Milli Q water with an observed 
pH of 3.2 (aqueous solvent) at pump A and as organic solventACN 
and methanol (1:1) at pump B at the flow rate 0.50 ml/min. The total 
LC run time was set at 7 min and the injection volume was 10 μL for 
each sample. However, the organic flow in gradient method was set 
at 10% flow from pump B (0.1 min to 1.0 min of total run time) and 
90 % flow was given of organic solvent from 1.0 min to 3.0 min and 
again back to 10% of the organic flow from 3.0 to 7.0 min to obtain 
an accurate chromatographic condition. The autosampler 
temperature was set at 15 °C and the pressure of the LC system was 
not more than 6000 psi. 
Mass equipment and optimization of mass parameters 
Acotiamide and Propranolol (IS) after separation by LC technique 
during method development, bioanalytical method validation and in 
biological samples were analyzed using an LC-MS/MS system (API 
2000, Applied Biosystems/MDS SCIEX, Toronto, Canada) by a triple 
quadrupole mass spectrometer coupled with turbo electrospray 
ionization (ESI) interface. For tuning parameters of the system 
1µg/ml of analyte and IS was scanned at a flow rate of 10 µl/min. Q1 
and Q3 scan of both Analyte and IS was done individually, and then 
it was processed for MRM scanning of Analyte and IS mixture for 
development of the bioanalytical method is optimized 
chromatographic condition summarized in table 1. The entire 
bioanalytical method was carried out in positive ionization mode. 
  
Table 1: Different mass parameters of instrument and component (analyte and IS) dependent parameters 
Parameters Values 
Instrumental parameters  
Source temperature ( °C) 400 
Curtain Gas 30 
CAD gas 5 
Ion spray voltage 5500 
Gas 1 45 
Gas 2 45 
Component dependent parameters 
 Drug IS 
Declustering potential (DP) 83 33 
Entrance potential (EP) 9.5 8.5 
Focusing potential (FP) 398 393 
Collision energy (CE)  29 28 
Cell exit potential (CXP) 3.5 3 
   
 
Plasma extraction and sample preparation 
A simple, less time consuming and accurate method of protein 
precipitation was followed for preparation validation and volunteer 
samples. 100 µl of blank plasma thawed at room temperature and 
taken in 2 ml Eppendorf tube, 50 µl of the stock solution along with 
50 µl of IS was mixed in Eppendorf tube and mixed by a vortex mixer 
for 1 min. Then, 300 µl of cold Acetronile was added and mixed and 
followed by vortex mixing again for 5 min. The resulted mixture was 
then was centrifuged at 12000 rpm for 10 min at 4±1 °C using a cold 
centrifuge. The upper supernatant layer was separated and put into 
an autosampler vial for injection purposes in LC-MS/MS. However, 
for the preparation of volunteer plasma samples, 150 µl of plasma 
sample is mixed with 50 µl IS and the remaining procedure was the 
same followed described previously.  
Method Validation 
Validation of the developed bioanalytical method was carried out 
according to ‘Guidance for Industry: bioanalytical method validation’ 
by the USFDA and EMA standard guideline. Different validation 
parameters including selectivity and specificity, accuracy and 
precision, linearity and lower limit of quantitation (LLOQ), recovery 
and matrix effect, and stability studies (Short term, Benchtop, 
Freeze-thaw, Autosampler stability, long term stability) was 
evaluated accordingly [11, 12, 16].  
Selectivity and specificity 
Selectivity is the ability of a bioanalytical method to differentiate and 
quantify the analyte in the presence of other components in the 
sample. The specificity of the method was assessed by six different 
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sources of blank plasma. This plasma was spiked with standard 
concentrations of the analyte along with IS at low, medium, and 
high-quality control samples, i.e., LQC, MQC, and HQC. 
Accuracy and precision 
Different QC concentrations of Drug and IS were prepared as QC 
batch in the Plasma sample and were analyzed with the developed 
method. The result was obtained and was expressed using standard 
calibration curves for 3 d (PA batch Day 1, Day 2, Day 3), to obtain 
inter-day precision and accuracy. Whereas, intraday precision and 
accuracy were obtained analysis of 5 sets of QC batch, extracted by 
blank plasma with different concentrations along with LLOQ of 
Acotiamide on three cumulative days, respectively. The precision 
was calculated in terms of 
coef icient of variation (CV (%)  =  standard deviation/mean x 100), 
and the accuracy was calculated as the 
Absolute Percent Bias (APB (%)  =  measured concentration/
targeted concentration x 100). 
The acceptance criteria of intra and inter-day batch for Precision 
and Accuracy batch were 20% or better for LLOQ and 15% or better 
for the rest of QC concentrations and the accuracy was within±20% 
or better for LLOQ and within±15% or better for the rest of QC 
concentrations. 
Linearity and lower limit of quantitation (LLOQ) 
Eight calibration standards i.e., 1.5625, 3.125, 6.25, 12.50, 25, 50, 
100, 200 ng/ml of acotiamide with a known and equal concentration 
of IS were added in blank plasma and analyzed to establish the 
Linearity of the method. The linearity range must be within±20% of 
the LLOQ and±15% other than LLOQ. The analyte peak in the LLOQ 
sample should be identifiable and reproducible with a precision 
of±20% and an accuracy of 80% to 120% according to standard 
guidelines [11, 12].  
Recovery and matrix effect 
The matrix effect is defined as the amount of erratic value produced 
during analysis due to the presence of endogenous substances 
present in a biological matrix. Sometimes, the alteration may cause a 
serious deviation of actual value, which is not permitted according 
to the guideline. Therefore, the matrix effect was calculated from QC 
standards with spiked plasma, at different concentrations. And the 
Recovery is calculated as QC samples spiked with the analyte or are 
with analyte spiked in blank plasma to ensure the reproducibility of 
the method [13]. 
Stability studies  
Different QC concentration samples spiked into blank plasma and 
kept in the deep freezer and were frozen at-20 °C, then it was 
thawed at room temperature and analyzed according to the protocol 
to check the Freeze-thaw Stability in three cumulative periods. The 
Autosampler stability of prepared samples established in 
Autosampler vials at a defined temperature at 15±2 °C for 24 h 
compared with freshly prepared control concentrations. In addition 
to that, the Benchtop stability was evaluated with the QC samples at 
room temperature which was kept for 8 h and was compared with 
fresh QC samples. The spiked analytes and IS in blank plasma kept in 
room temperature for 6 h and the short term stability was 
established against fresh control concentrations. However, Long 
term stability was necessary to evaluate with prepared QC samples 
prepared on day 1 of validation till 15thday and compared with 
freshly prepared QC samples according to USFDA and EMA 
guidelines. The precision and accuracy for the stability samples must 
be within ≤15% and±15% respectively of fresh QC concentrations 
[11-13]. 
RESULTS AND DISCUSSION 
Liquid chromatography 
The presence of an amide group in the parent structure makes it 
basic; therefore, the acidic mobile phase was used for separation. 
Though, different mobile phases for organic pumps ranging from 
ACN or Methanol with different buffers of different pH used to 
obtain a good resolution with acceptable peak shape. However, after 
a few trials and errors, 0.1% formic acid as a modifier in Mili Q water 
with an observed pH of 3.2 (aqueous solvent) at pump A and as 
organic solvent ACN and methanol (1:1) at pump B was used using 
gradient technique. In LC parameters, the gradient flow of aqueous 
flow of 90% flow was set to obtain maximum retention of the matrix 
interferences by LC. Whereas Phenomenex Kinetex C18; 50 x 3 mm 
column was used as a stationary phase which showed better 
retention of the matrix components that provide good separation 
and peak shapes [13].  
Mass spectrometry 
For the optimization of mass parameters each analyte and IS was 
introduced into the mass quadrupole initially during the method 
development phase Haward syringe pump method was used where 
10 µl of flow was maintained. As Acotiamide contains a basic amide 
group, which can readily accept proton for ionization, positive 
ionization mode was used, which showed a maximum response. 
After system tuning the method was checked in MRM mode using 
electrospray as ionization (ESI) source. The mass parameters, i.e., 
Curtain Gas, CAD gas, Ion spray voltage, Gas 1, Gas 2 was set and 
optimized, and simultaneously compound dependent parameters 
(listed in table 1) also set to obtain good resolution and 
symmetrically shaped peaks in chromatography. The most 
abundant protonated ions [m+H]+ obtained by collision-induced 
dissociation of Acotiamide and IS (Propanolol) in the Q1 spectrum, 
was used as production in Q3. The precursor to production reactions 
was m/z 451.200→ 271.200for Acotiamide and m/z 260.300→ 
116.100 for IS. The ionization pattern of Acotiamide and IS 
(Propanolol) from Q1 to Q3 shown in fig. 1 and fig. 2, respectively. 
M/z and Retention time of analyte and IS were set as acceptance 
criteria for the identification parameter of compounds [14, 15]. 
However, identification and quantification of the analytes were 
evaluated and produced in chromatograms according to the ratios of 
signal-to-noise (S/N), S/N ≥ 3, and S/N ≥ 10, respectively. Final MRM 
scan of Analyte and IS shown in fig. 3. 
Method validation 
Method validation was carried to establish the acceptance of a 
prepared method according to the US FDA and EMA guidelines along 
with other published acceptance criteria [11, 12]. Standard 
validation parameters i.e., linearity, accuracy, precision, recovery, 
and sample stability, were studied and obtained results with 
chromatograms shown below. As the study and method mainly 
govern with plasma samples, it was highly recommended to check 
the matrix effect to find any endogenous interactions if any.  
Selectivity and specificity 
No interfering peaks were observed at the retention times of 
Acotiamide and are in human blank plasma. It showed that the 
developed analytical method was specific for the analysis. 
Accuracy and precision 
The intraday and inter-day accuracy and precisions were checked 
using high medium and low QC samples prepared in human 
plasma for Acotiamide and IS. The precision of both intra and 
inter-day was calculated from the relative standard deviation. 
Interday precision obtained by analyzing the same QC batch and 
by the same extraction procedure in previously tuned LC-MS/MS 
methods ( =3 d). Inter day precision values (%CV) ranged from 
4.514 to 8.917 %. Inter day accuracy values (% nominal) were 
103.25% for (LLOQ), 102.02% for low QC (LQC), 94.88% for 
medium QC (MQC), and 96.52% for high QC (HQC) samples. 
Intraday precision values (%CV) ranged from 5.658% to 8.389%. 
Intraday accuracy values (% nominal) were 91.26% for (LLOQ), 
103.51% for low QC (LQC), 102.45% for medium QC (MQC) and 
96.58% for high QC (HQC) samples. Inter day and Intraday 
Accuracy and Precision for Acotiamide summarized in table 2. 
These obtained results indicated that the developed method was 
accurate and reproducible. 
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Fig. 1: Ionization pattern of acotiamide from Q1 to Q3 
 
 
Fig. 2: Ionization pattern of IS (Propanolol) Q3 
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Fig. 3: Typical MRM chromatograms of Acotiamide and Propanolol (IS) in blank plasma spiked of Acotiamide at LLOQ (1.5625 ng/ml) with IS 
 
Table 2: Inter day and intraday accuracy and precision for acotiamide (n=5) 
 (Between run) inter-day precision and accuracy  (Within run) intraday precision and accuracy 
 Mean SD C. V.% Accuracy Mean SD C. V.% Accuracy 
LLOQ 1.5625 ng/ml 1.613 0.144 8.917 103.25 1.426 0.113 7.897 91.26 
LQC 4.6875ng/ml 4.782 0.276 5.776 102.02 4.852 0.275 5.658 103.51 
MQC 75 ng/ml 71.161 3.212 4.514 94.88 76.834 6.446 8.389 102.45 
HQC 150 ng/ml 144.776 9.268 6.402 96.52 144.868 8.453 5.835 96.58 
 
 
Fig. 4: The representative calibration curve of PA batch Day 1 for acotiamide 
 
Linearity, the lower limit of detection (LOD) and lower limit of 
quantitation (LLOQ) 
LOD was found 0.78125 ng/ml and LLOQ was 1.5625 ng/ml in this 
validated method and the intra and inter-day CV% was determined 
between 1.28 to 14.15, which proved that the method was sensitive 
enough and validated precisely. Hence, a representative 
chromatogram showing LLOQ is shown in fig. 3. 
The eight-point standard curve was linear over the wide range of 
calibration 1.5625 to 200 ng/ml, which gives acceptable results 
during the quantification of unknown concentration of the drug in 
human plasma by plotting AUC of analyte AUC of IS on the curve. 
Calibration curve of PA batch day 1 for Acotiamide shown in fig. 4. 
The mean correlation coefficient for the linearity equation was 
determined to be 0.9953 using the regression equation 
y=0.0001x+642333.33 (y = mx + c) where y and x denote analyte 
PA BATCH DAY 1_MV_ACOTIAMIDE.rdb (Acotiamide): "Linear" Regression ("1  / (x * x)" weighting): y = 0.000155 x + 6.47e-005 (r = 0.9972)
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area IS area and analyte concentration/IS concentration, 
respectively. 
Recovery and matrix effect 
Recovery results have shown that the maximum recovery was 
carried out with both Acotiamide and IS above 90%. The extraction 
recovery was achieved to be satisfactory as it was consistent, 
precise, and reproducible. Hence single-step protein precipitation 
technique used in this method proved to be efficient and simple 
enough to extract drugs with IS from human plasma. 
No significant matrix effect, i.e., ion suppression or enhancement 
was noticed by comparing the area under the curve (AUC) ratios of 
the extracted QCs and IS with the AUC of unextracted QCs and IS 
acquired from the injecting aqueous solution prepared at same 
concentrations. No interferences from endogenous compounds were 
found in the six different sources of human plasma. Therefore, it 
shows that the extracts were ‘‘clean’’ with no co-eluting ‘‘unseen’’ 
components which interfere with the ionization of both the analyte 
and IS. Recovery and matrix effect of Acotiamide summarized in 
tables 3 and 4, respectively. 
  
Table 3: Recovery of acotiamide and IS from plasma 
 Acotiamide IS 
Mean area (%) recovery Mean area (%) recovery 
LQC (4.6875 ng/ml) 2737.85 93.68 3382127.94 95.70 
MQC (75 ng/ml) 39645.69 91.49 3362235.21 95.41 
HQC (150 ng/ml) 76306.48 92.00 3444570.48 102.60 
 
Table 4: Matrix effect of acotiamide from a different source of human plasma (n=5) 
 Matrix effect (% ME) Mean SD %CV 
1ST SET 2ND SET 3RDSET 4TH SET 5TH SET 
LQC (4.6875 ng/ml) 90.13 83.81 85.22 90.61 106.32 91.22 8.95 9.81 
MQC (75 ng/ml) 90.62 84.49 91.71 78.30 88.13 86.65 5.43 6.27 
HQC (150 ng/ml) 87.24 77.18 82.92 94.43 94.97 87.35 7.60 8.70 
 
Stability studies  
The different stability studies all carried out with freshly prepared QC 
concentrations of different concentrations. Freeze-thaw stability was 
checked with QC concentrations spiked in blank plasma which was kept 
in the deep freezer and thawed in room temperature, compared with 
freshly prepared QC samples. The stability of Acotiamide ranges 
between 96.34% to 106.43%. It was also found in the Short term (24 h) 
stability study, low, medium and high QC samples were compared 
against freshly prepared QC samples of the same concentration. The 
short term stability of Acotiamide ranges between 100.80%-108.55% 
after three cycles. Another stability parameter, Autosampler stability, 
was checked with QC samples stored in Autosampler vials for 24 h 
with freshly prepared samples. The obtained results of Autosampler 
stability ranged from 85.94% and 97.08%. Long term stability of 30 d 
was checked for low and high-quality control samples against samples. 
The obtained result ranges from 88.91% and 98.37%. All the stability 
study results of all QC samples summarized in table 5. 
  
Table 5: Stability of different QC standards in the different storing condition of acotiamide (mean±SD, n=5) 
Stability studies QC samples mean±SD %CV 
Short term Stability LQC (4.6875ng/ml) 5.02±0.28 100.80 
MQC (75 ng/ml) 78.61±4.33 108.55 
HQC (150 ng/ml) 144.62±4.62 106.47 
Auto Sampler Stability LQC (4.6875ng/ml) 4.28±0.26 85.94 
MQC (75 ng/ml) 65.08±1.76 89.87 
HQC (150 ng/ml) 131.87±2.67 97.08 
Bench Top Stability Study LQC (4.6875ng/ml) 4.88±0.44 98.11 
MQC (75 ng/ml) 71.47±2.33 98.70 
HQC (150 ng/ml) 143.70±10.89 105.79 
Long Term Stability LQC (4.6875ng/ml) 4.43±0.23 88.91 
MQC (75 ng/ml) 69.32±4.38 95.72 
HQC (150 ng/ml) 133.62±5.27 98.37 
Freeze-Thaw Stability LQC (4.6875ng/ml) 4.80±0.13 96.34 
MQC (75 ng/ml) 76.27±6.28 105.33 
HQC (150 ng/ml) 144.57±9.43 106.43 
 
Pharmacokinetics evaluation and application of the method 
A comparative clinical study was conducted in 24 healthy human 
volunteers consisting of two different phases of the study, in each 
phase volunteers received alternatively test and reference drug 
formulations according to the prescribed manner [17-20]. The utility 
of the study was also emphasized on establishing the measure of the 
safety of Acotiamide in healthy volunteers. Generally, it was found in 
earlier literature that, Acotiamide undergoes a rapid absorption, 
therefore, the maximum plasma level reaches within the first hour, 
and it was found that within the study period, no adverse reactions 
occurred to any volunteer in both phases. So, it can be concluded 
that the finished product is safe in the Indian population.  
In this present study, it was found that both the treatments were 
well tolerated and no SAE (serious adverse event) was reported 
from the clinical aspect. The pharmacokinetic comparison of 
both test and reference was shown in table 6. The representative 
chromatogram for the volunteer plasma sample is shown in fig. 
5. The mean terminal half-life of orally administered Acotiamide 
reference and test medications were 23.49±5.09 and 24.54±4.86 
h, respectively. In addition to that, the mean AUC0-t 
(421.52±101.96 and 417.72128.93ng. hr./ml for test and 
reference respectively) and Cmax (25.71±2.31 and 23.61±2.32 
ng./ml for test and reference respectively) were not significantly 
different, and the 90% confidence interval obtained in the 
statistical evaluation and shown in table 7 (using the SAS 
software and ANOVA) [21]. It was found that the obtained 90% 
confidence interval satisfactory following US-FDA and the EMA 
guideline. Mean drug plasma concentration-time profile curve of 
Acotiamide is shown in fig. 6. 
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Table 7: 90% Confidence 
Acotiamide 100 mg tablet 
 Untransformed
Cmax M = 0.92, 90% CI [0.8797, 0.9603].
AUCo-t M = 
AUC0-inf M = 0.99, 90% CI [0.8523, 1.1277]
Relative bioavailability 99.10%
 
Fig. 5: Representative MRM chromatograms of volunteer plasma samples of (A) 
Fig. 6: Graphical representation of mean plasma concentration versus time of Acotiamide 10
preparation in 24 healthy human volunteers, 
DISCUSSION 
The method developed for quantification of Acotiamide was done in 
human plasma and pharmacokinetic parameters were calculated 
after oral administration in healthy human volunteers. As we 
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interval calculation for untransformed and Ln transformed pk parameters
 Ln transformed
 M = 0.98, 90% CI [0.9733, 0.9867].
0.98, 90% CI [0.8625, 1.0975] M = 1, 90% CI [0.98, 1.02].
 M = 1, 90% CI [0.98, 1.02].
  
Acotiamide and (B) Propanolol (IS) in human volunteer 
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pharmacodynamic point of view, the therapeutic concentration 
persists for a longer period. For the development of the bioanalytical 
method to determine pharmacokinetic parameters using LC-MS/MS, 
a simple method was developed, which involved an easy, time-
efficient, and cost-effective protein precipitation technique for the 
extraction of drugs in plasma samples.  
After analyzing the clinical data of Acotiamide, it was found that the 
drug is safe upon administration in healthy human subjects. In each 
study period, no adverse event was found; therefore, the drug is well 
tolerated in individuals. The comparative pharmacokinetic outcome 
showed that the test and reference product having an almost similar 
pattern of pharmacokinetics. Although it was found that the test is 
bioequivalent comparing to the reference product. The drug here, 
Acotiamide was first introduced by Japan as a prokinetic agent, which 
enhances acetylcholine release from enteric neurons by antagonizing 
muscarinic receptors (M1)and acetylcholinesterase inhibition, which 
results enhancing gastric emptying [14]. In the formulation, 
Acotiamide hydrochloride hydrate was used, which is highly water-
soluble and offers a good absorption rate in the systemic circulation. 
On the other hand, so far to our knowledge, none of the reported 
bioanalytical procedures describe a method for the determination of 
Acotiamide in human plasma by LC-MS/MS. Previously, the only 
pharmacokinetic study was carried out using LC-MS/MS done in Rat 
plasma, so it was essential to evaluate the pharmacokinetic study in 
human plasma to establish a firm clinical significance in the human 
population [22]. In the present study, attempts were made to 
develop and validate a sensitive, selective, precise, accurate, rapid, 
and economical method for the determination of Acotiamide in 
human plasma by LC-MS/MS. 
CONCLUSION 
Based on a comparison of the AUC0-t for Acotiamide after single-dose 
administration, the relative bioavailability of the test was found to be 
99.10% compared to reference preparation. No occurrence of adverse 
events was reported by the subjects throughout the study duration. 
Therefore it may be concluded that the test preparation was found to 
be bioequivalent with the reference preparation. Finally, a simple, 
sensitive, selective, and rapid LC-MS/MS bioanalytical method has 
developed for the determination of Acotiamide in human plasma for 
the very first time. The developed method is at par with the standard 
industry guidelines for validation. The developed bioanalytical method 
is demonstrated highly specific due to the inherent selectivity of 
tandem mass spectrometry. The validation results have been proved 
that the developed LC-MS/MS method is satisfied with all the 
parameters within range, i.e., specificity, sensitivity, linearity, 
precision, accuracy, and stability. A simple and convenient extraction 
procedure, i.e. protein precipitation technique (PPT) with used only 
150 μL of human plasma makes this method more advantageous for 
the bioanalysis of Acotiamide. The resulted pharmacokinetic 
parameters would be helpful to provide some guidance to clinical 
application and investigation. 
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